Sanofi Price to Sales Ratio 2010-2023 | SNY
Historical PS ratio values for Sanofi (SNY) over the last 10 years. The current P/S ratio for Sanofi as of May 09, 2024 is .
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
| Sanofi P/S Ratio Historical Data |
| Date |
Stock Price |
TTM Sales per Share |
Price to Sales Ratio |
| 2024-05-09 |
48.69 |
|
2.43 |
| 2023-12-31 |
47.73 |
$20.07 |
2.38 |
| 2023-09-30 |
51.49 |
$19.56 |
2.63 |
| 2023-06-30 |
51.74 |
$19.33 |
2.68 |
| 2023-03-31 |
50.34 |
$19.24 |
2.62 |
| 2022-12-31 |
44.80 |
$19.09 |
2.35 |
| 2022-09-30 |
35.17 |
$19.45 |
1.81 |
| 2022-06-30 |
46.28 |
$14.17 |
3.26 |
| 2022-03-31 |
45.96 |
$13.89 |
3.31 |
| 2021-09-30 |
43.16 |
$13.98 |
3.09 |
| 2021-06-30 |
47.14 |
$12.99 |
3.63 |
| 2021-03-31 |
42.66 |
$17.40 |
2.45 |
| 2020-09-30 |
43.27 |
$17.07 |
2.53 |
| 2020-03-31 |
36.39 |
$16.47 |
2.21 |
| 2019-09-30 |
38.56 |
$16.54 |
2.33 |
| 2019-03-31 |
35.37 |
$16.54 |
2.14 |
| 2018-03-31 |
30.56 |
$16.48 |
1.85 |
| 2017-12-31 |
32.79 |
$16.30 |
2.01 |
| 2017-09-30 |
37.97 |
$16.15 |
2.35 |
| 2017-06-30 |
36.53 |
$15.40 |
2.37 |
| 2016-12-31 |
29.83 |
$14.89 |
2.00 |
| 2016-09-30 |
28.17 |
$15.19 |
1.85 |
| 2016-06-30 |
30.87 |
$15.17 |
2.03 |
| 2016-03-31 |
28.41 |
$15.77 |
1.80 |
| 2015-09-30 |
33.58 |
$16.30 |
2.06 |
| 2015-06-30 |
35.04 |
$16.63 |
2.11 |
| 2014-06-30 |
36.43 |
$16.88 |
2.16 |
| 2013-06-30 |
34.07 |
$17.03 |
2.00 |
| 2012-06-30 |
24.14 |
$17.62 |
1.37 |
| 2012-03-31 |
23.66 |
$17.83 |
1.33 |
| 2011-12-31 |
22.31 |
$17.94 |
1.24 |
| 2011-09-30 |
20.02 |
$17.40 |
1.15 |
| 2011-06-30 |
24.52 |
$17.02 |
1.44 |
| 2011-03-31 |
20.78 |
$16.45 |
1.26 |
| 2010-12-31 |
19.02 |
$15.82 |
1.20 |
| 2010-09-30 |
19.62 |
$15.82 |
1.24 |
| 2010-06-30 |
17.74 |
$15.87 |
1.12 |
| 2010-03-31 |
21.27 |
$15.83 |
1.34 |
| 2009-12-31 |
22.35 |
$15.62 |
1.43 |
| 2009-09-30 |
21.03 |
$15.51 |
1.36 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$123.167B |
$46.611B |
|
Sanofi-Aventis manufactures & markets prescription drugs across countries. It focuses on major therapeutic areas such as multiple sclerosis, cardiovascular, immunology, neurology, oncology, rare blood disorders & diabetes, etc. By taking Genzyme Corporation as a subsidiary, it added products like Cerezyme, Myozyme/Lumizyme & Fabrazyme to its portfolio. Sanofi has become a major player in the CHC sector. It acquired many companies i.e. Ablynx & Bioverativ, Synthorx & Principia & Translate Bio and Kadmon. It has collaborated with companies like Regeneron among others. It develops and markets Dupixent, Kevzara & Libtayo in collaboration with Regeneron. Sanofi, along with Regeneron, is now solely responsible for Praluent marketing in & outside the U.S. Sanofi operates through 3 Global Business Units: Specialty Care (neurology & immunology, rare diseases, rare blood disorders & oncology), Vaccines & General Medicines (diabetes, cardiovascular & established products) and Consumer Healthcare, a standalone unit.
|
